Sartorius Stedim Biotech: share up thanks to Barclays

(CercleFinance.com) - Sartorius Stedim Biotech was one of the biggest risers in the SBF 120 index on Wednesday morning on the Paris Bourse, buoyed by an upgrade from Barclays analysts.


The broker hails the emergence of a "new world" for the pharmaceutical and biopharmaceutical manufacturing industry, of which Sartorius Stedim Biotech is one of the two leading specialists in Europe, along with its parent company Sartorius.

According to its calculations, the sector is now only one quarter away from a return to the normal trajectory that would have characterized it without the emergence of Covid.

Despite this, both Sartorius Stedim Biotech and Sartorius are trading at much lower valuation levels than their peers, points out Barclays, which has accordingly upgraded Sartorius Stedim Biotech from 'equal weight' to 'overweight', with a price target raised from E200 to E250.

The share price rose by over 2.5% on Wednesday morning in the wake of these comments.


Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.